Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH lutein study

This article was originally published in The Tan Sheet

Executive Summary

The second Age-Related Eye Disease Study (AREDS II) is slated to begin in Spring 2006, according to its sponsor, the National Eye Institute. The Phase III clinical trial will investigate whether oral supplementation with lutein (10 mg/day) and zeaxanthin (2 mg/day) and/or lutein and zeaxanthin in combination with omega-3 fatty acids (1 g/day) will slow the progression of age-related macular degeneration (AMD) when compared to placebo. Participants will be at moderate to high risk of AMD. The supplements' effect on cataract surgery also will be examined. To date, more than $4 mil. in funding has been awarded. The study builds off the first AREDS, which found that high-dose combination of antioxidants and zinc can lower the risk of developing advanced AMD in high-risk patients (1"The Tan Sheet" Oct. 15, 2001, p. 3)...
Advertisement

Related Content

AREDS II update
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS098988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel